Investigating the effect of letrozole in the treatment of ectopic pregnancy

Investigating the effect of letrozole in the treatment of ectopic pregnancy and comparing its therapeutic effect with methotrexate

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220902055855N1

Enrollment

Registered

2023-04-13

Start date

2023-05-22

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic pregnancy. Ectopic pregnancy

Interventions

Intervention 1: The first intervention group received letrozole with the brand name Letrofem 2.5 mg orally by Iran Hormon Company for a period of 10 days, two oral doses in the morning at the same tim

Eligibility

Sex/Gender

Female

Age

18 Years to 45 Years

Inclusion criteria

Inclusion criteria: All patients diagnosed with ectopic pregnancy who are candidates for medical treatment

Exclusion criteria

Exclusion criteria: Unstable patients and candidates for surgical treatment The presence of fetal heart activity in the gestational sac BHCG level is more than 3000

Design outcomes

Primary

Measure	Time frame
Decreased bhcg trend. Timepoint: First, seventh, fourteenth day. Method of measurement: Use of defined laboratory criteria.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzadeh Tarafdari manshadi

Tehran University of Medical Sciences

tarafdari@sina.tums.ac.ir+98 21 6119

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026